ArticleEuropean journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology2026
Evaluation of clinical efficacy and safety of T-705 (Favipiravir) in the treatment of fever with thrombocytopenia syndrome: a propensity score matching study.
Article in European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
objectiveSevere Fever with Thrombocytopenia Syndrome (SFTS), an emerging infectious disease of essential public health concern, currently lacks specific antiviral treatments, This study evaluated the efficacy of the broad-spectrum antiviral drug T-705 (Favipiravir).
methodsUsing propensity score matching (PSM) to minimize confounding factors between T-705 and Non-T-705 groups, Absolute Shrinkage and Selection Operator (LASSO) regression and multivariate logistic regression were used to screen the factors affecting the efficacy of T-705.
resultsAnalysis revealed a consistently higher disease improvement rate in the T-705 group (82.3% Pre-PSM, 80.6% Post-PSM) compared to Non-T-705 group (67.3%), with the difference remaining statistically significant (P = 0.032) after PSM. The results demonstrated that Ct values (1.397, 1.168-1.671, P < 0.001), lactate dehydrogenase (LDH) (1.002, 1.001-1.003, P = 0.027) and albumin (ALB) (1.153, 1.001-1.330, P = 0.050) levels were the protective factor for disease improvement, while clinical type (0.146, 0.045-0.477, P = 0.001), age (0.942, 0.893-0.994, P = 0.030), activated partial thromboplastin time (APTT) (0.917, 0.873-0.963, P < 0.001), total bilirubin (TBIL) (0.867, 0.752-0.999, P= 0.048), creatinine (CREA) (0.992, 0.985-0.999, P = 0.038) and uric acid (UA) (0.994, 0.990-0.999, P = 0.017) levels were risk factors for disease improvement.
conclusionsThe study demonstrated that T-705 exhibited significant efficacy and favorable safety in the treatment of SFTS patients. Furthermore, a multivariate logistic regression verified its clinical significance, thereby providing robust evidence to support its inclusion in treatment guidelines.
Indexed as
Identifiers
41484505What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.